Medexus Pharmaceuticals Management
Management criteria checks 3/4
Medexus Pharmaceuticals' CEO is Ken d'Entremont, appointed in Dec 2018, has a tenure of 5.42 years. total yearly compensation is $882.21K, comprised of 45.3% salary and 54.7% bonuses, including company stock and options. directly owns 5.98% of the company’s shares, worth €1.76M. The average tenure of the management team and the board of directors is 4.1 years and 5.6 years respectively.
Key information
Ken d'Entremont
Chief executive officer
US$882.2k
Total compensation
| CEO salary percentage | 45.3% |
| CEO tenure | 5.4yrs |
| CEO ownership | 6.0% |
| Management average tenure | 4.1yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$6m |
| Sep 30 2023 | n/a | n/a | US$5m |
| Jun 30 2023 | n/a | n/a | US$3m |
| Mar 31 2023 | US$882k | US$400k | US$1m |
| Dec 31 2022 | n/a | n/a | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | US$2m |
| Mar 31 2022 | US$592k | US$400k | -US$3m |
| Dec 31 2021 | n/a | n/a | -US$8m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | US$688k | US$328k | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$19m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | US$385k | US$300k | -US$5m |
| Dec 31 2019 | n/a | n/a | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$3m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | US$2m | US$144k | -US$5m |
Compensation vs Market: Ken's total compensation ($USD882.21K) is above average for companies of similar size in the German market ($USD402.64K).
Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.
CEO
Ken d'Entremont
5.4yrs
Tenure
US$882,209
Compensation
Mr. Kenneth d'Entremont, also known as Ken, has been Chief Executive Officer at Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) since December 2018 and served as its Chief Operating Officer since O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.4yrs | US$882.21k | 5.98% $ 1.8m | |
| Chief Financial Officer | 2.8yrs | US$702.56k | 0.33% $ 96.5k | |
| General Counsel & Corporate Secretary | 2.5yrs | US$464.02k | 0.084% $ 24.9k | |
| Executive of Investor Relations | no data | no data | no data | |
| Senior Vice President of Commercial Operations - United States | 5.6yrs | US$439.69k | no data | |
| Vice President of Sales & Marketing - United States | no data | US$281.91k | no data |
4.1yrs
Average Tenure
Experienced Management: P731's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$882.21k | 5.98% $ 1.8m | |
| Independent Chairman | 10yrs | US$139.92k | 0.37% $ 108.4k | |
| Independent Director | 6.7yrs | US$145.95k | 0.23% $ 68.0k | |
| Independent Director | 5.6yrs | US$124.92k | 2.24% $ 659.9k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.3yrs | US$60.18k | 0.054% $ 16.0k | |
| Independent Director | 1.3yrs | US$60.18k | 0.054% $ 16.0k |
5.6yrs
Average Tenure
54yo
Average Age
Experienced Board: P731's board of directors are considered experienced (5.6 years average tenure).